Patent intelligence · US
US 10537560
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
Patent details — US 10537560
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 21, 2020
- Expiration
- Jan 16, 2040
- Applicant
- Fulcrum Therapeutics, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4418
Quick answer
US 10537560 (P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD) is held by Fulcrum Therapeutics, Inc.. Status: granted. Granted Jan 21, 2020. Expires Jan 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4418, A61K31/4439, A61K31/454
More from Fulcrum Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12109198
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11819554
Compositions and methods for modulating FMR1 expression
granted -
US 11590111
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11479770
Use of p38 inhibitors to reduce expression of DUX4
granted -
US 11291659
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10973805
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 10342786
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted
Frequently asked questions
What is US patent 10537560?
US 10537560 (P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD) is held by Fulcrum Therapeutics, Inc.. Status: granted. Granted Jan 21, 2020. Expires Jan 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10537560?
Fulcrum Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 10537560 expire?
Our index shows an expiration date of Jan 16, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.